41 results about "Lymphoblast" patented technology

The invention provides a blood analyzer comprising a blood sample supply section, a sample preparation section for preparing an assay sample by mixing the blood sample with a nucleic acid-staining fluorescent dye, a light source for irradiating the assay sample, an optical detecting section for receiving fluorescence emitted from the irradiated assay sample and a controller for performing operations comprising detecting a cell group comprising lymphoblasts on the basis of the fluorescence received by the optical detecting section, and outputting an information on an appearance of the lymphoblasts in the blood sample, as well as a method for determining the existence and nonexistence of lymphoblasts in a blood sample.

The disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a purine analog for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.

The invention discloses an IFN-Alpha subtype compound generated by lymphoblast, which is characterized in that the rarefied IFN-Alpha compound has higher specific activity, and can be used to cure cancer, virus and immunity diseases.

Changes that occur in Na⁺K⁺ ATPase regulation and therefore in the membrane potential in cells from bipolar individuals, as compared to cells from unaffected control individuals, are utilized to provide a diagnostic assay for bipolar I and bipolar II disorders. The diagnostic assay may also or instead exploit the similarity of cells from new patients to those of people already known to have bipolar I or bipolar II disorder. A similar diagnostic assay is provided for diagnosing attention-deficit/hyperactivity disorder (ADHD) and unipolar disorder. The diagnostic assays may further involve manipulation of membrane potential by incubation of cells in K⁺-free buffer and/or incubation with one or more compounds that alter Na⁺K⁺ ATPase activity. Although a variety of cells may be used, the diagnostic assays preferably employ lymphoblasts or whole blood cells.

The invention provides an artificial intelligence identification method for a peripheral hemolymph micronucleus cell image, and the method comprises the steps: collecting a to-be-analyzed sample through a collection device, and obtaining a cell image; carrying out segmentation processing on the obtained cell image to obtain a foreground to-be-detected area; identifying, classifying and counting the cells on the foreground to-be-detected area; storing the cell type information on the foreground to-be-detected area and the position information of the foreground to-be-detected area on the cell image to form traceable information; and forming an image-text report according to the traceable information, and storing the image-text report as an artificial intelligence system learning training material. According to the artificial intelligence identification method for the peripheral hemolymph micronucleus cell image provided by the invention, automatic identification and classification of specific images of lymphoblasts, micronucleus cells and nude nuclei of peripheral blood can be realized. Compared with an existing microscope artificial microscopic examination method, the statistical accuracy is higher, and the detection speed is remarkably increased.

The invention discloses the method for separating pluripotent ancestral cell from umbilical cord blood, comprising the following steps: using lymphoblast to separate umbilical cord blood monocyte, culturing for 3 days at culture medium with 8-15% bovine serum, throwing away cell which is not sticked on wall, replacing the culture medium with 2-5% bovine serum, bFGF, EGF, PDGF-BB, MCDB-201, ascorbic acid, anaflogistico and ITS addition agent, culturing, passage purifying, and separating. The method has the advantages of high separation rate. The cell phenotype, cell periodic time and evoked differentiation ability are the same.

The invention discloses a method for separating Pig-a gene mutant cells from cells cultured in vitro and application of the Pig-a gene mutant cells. The method comprises the following steps: (1) mixing an anti-GPI anchorage protein antibody marked by an immunofluorescent dye, magnetic beads resisting the immunofluorescent dye and the cells; and (2) separating cells marked by the magnetic beads from cells not marked by the magnetic beads, wherein the cells marked by the magnetic beads being Pig-a gene mutation negative cells, and the cells not marked by the magnetic beads being Pig-a gene mutation positive cells. The method provided by the invention has higher separation efficiency for removing cells, such as the Pig-a positive cells pre-stored in human lymphoblastic TK6 cells, can separate10 million cells within 15 minutes, and is simple to operate and low in cost.

This invention relates to methods and compositions useful for detecting mutations which cause Familial Dysautonomia. Familial dysautonomia (FD; Riley-Day syndrome), an Ashkenazi Jewish disorder, is the best known and most frequent of a group of congenital sensory neuropathies and is characterized by widespread sensory and variable autonomic dysfunction. Previously, we mapped the FD gene, DYS, to a 0.5 cM region of chromosome 9q31 and showed that the ethnic bias is due to a founder effect, with >99.5% of disease alleles sharing a common ancestral haplotype. To investigate the molecular basis of FD, we sequenced the minimal candidate region and cloned and characterized its 5 genes. One of these, IKBKAP, harbors two mutations that can cause FD. The major haplotype mutation is located in the donor splice site of intron 20. This mutation can result in skipping of exon 20 in the mRNA from FD patients, although they continue to express varying levels of wild-type message in a tissue-specific manner. RNA isolated from patient lymphoblasts is primarily wild-type, whereas only the deleted message is seen in RNA isolated from brain. The mutation associated with the minor haplotype in four patients is a missense (R696P) mutation in exon 19 that is predicted to disrupt a potential phosphorylation site. Our findings indicate that almost all cases of FD are caused by an unusual splice defect that displays tissue-specific expression; and they also provide the basis for rapid carrier screening in the Ashkenazi Jewish population.

The invention discloses a traditional Chinese medicinal preparation for treating malignant tumors. The traditional Chinese medicinal preparation is prepared by combing such traditional Chinese medicines as rhizoma sparganii, curcuma zedoary, fritillaria cirrhosa, edible tulip, trametes robiniphila murr, fructus camptothecae acuminatae, ganoderma lucidum spore powder, saffron crocus, cinnabar, semen strychni, indigo naturalis, rheum officinale, dragon's blood, oldenlandia diffusa, natural calculus bovis, musk, antelope horn, scorpion, centipede, bombyx batryticatus, geckos, pangolin, blood amber, tortoise-plastron glue, colla cornus cervi and the like. On the basis of a synergistic effect generated from the combined medicinal materials which combine tonification and purgation and supplement each other, the traditional Chinese medicinal preparation is not only relatively strong in effect of inhibiting tumor cells, but also capable of better improving immunity of patients, promoting transformation of lymphoblast, enhancing functions of a reticuloendothelial system, promoting the generation of immune globulins and improving disease resistance of the patients. Due to the technical scheme, the traditional Chinese medicinal preparation, compared with the prior art, has the advantages of being simple to take, low in toxic and side effects, unique in curative effect and the like, and the traditional Chinese medicinal preparation is capable of treating both symptoms and root causes.

The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a BCL-2 inhibitor for the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.

The invention relates to the technical field of medical detection, and particularly relates to a method for detecting lymphocyte transformation by utilizing a medicament cytochalasins B. According to the invention, the principle that peripheral blood lymphocytes can be transformed into lymphoblasts which are divisive after being stimulated by phytohemagglutinin in vitro and the principle that the cytochalasins B can retard cell division but can not retard cell nucleus division are utilized, 2 Gyg ray irradiation is carried out on the peripheral blood of a human body for further realizing immunodepression, and PHA (phytohemagglutinin) stimulation is carried out and the cytochalasins B is added for treatment, so that the difference between the dikaryon rate of radiated lymphocytes and the dikayron rate of non-irradiated lymphocytes is detected. The result shows that transformed lymphocytes can form dikaryocytes, the dikaryon rate of the radiated lymphocytes can be obviously reduced, the immunity of radiated T lymphocytes can be obviously inhibited, and the dikaryon rate can better reflect the immune function of the lymphocytes. The method is intuitive, simple in operation, rapid, economical, and accurate in result during detection of indexes.

The invention relates to the field of medicinal chemistry, in particular to application of an indolo[3,2-a]carbazole derivative with the general formula shown in a formula I in preparation of a drug for resisting tumors, and definitions of all substituent groups are shown in the description.The indolo[3,2-a]carbazole derivative has good activity in human erythrocyte leukemic (HEL) cells, leukemia cells K562-1, human melanoma cells WM9-1, breast cancer cells MDA-MB231, human lymphoblast TK6 and prostate cancer cells PC-3 and has a good research and development prospect.(Please see the formula I in the description.).